Common pigmentation disorders

American Family Physician

Volumn 79, Issue 2, 2009, Pages 109-116

  Plensdorf, Scott ^a   Martinez, Joy ^b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPALENE; AZELAIC ACID; BETAMETHASONE DIPROPIONATE; FLUOCINONIDE; GLYCOLIC ACID; HYDROQUINONE; MEQUINOL PLUS RETINOIC ACID; MONOBENZONE; PHENYTOIN; PSORALEN; RETINOIC ACID; RETINOID; SALICYLIC ACID; STEROID; SUNSCREEN; TACROLIMUS; TAZAROTENE; TRICHLOR; TRICHLOROACETIC ACID; UNCLASSIFIED DRUG;

ACNE; ATOPIC DERMATITIS; BEDTIME DOSAGE; BURN; CAFE AU LAIT SPOT; CARBON DIOXIDE LASER; CHLOASMA; CRYOTHERAPY; DEPIGMENTATION; DIFFERENTIAL DIAGNOSIS; DRUG HYPERSENSITIVITY; DRY SKIN; ECZEMA; EPHELIDE; HUMAN; HYPERPIGMENTATION; HYPOMELANOSIS; HYPOPIGMENTATION; IRRITANT DERMATITIS; LENTIGO; LOW LEVEL LASER THERAPY; MELANOSIS; NEODYMIUM LASER; OCHRONOSIS; PARAPSORIASIS; PATHOPHYSIOLOGY; PHOTOTHERAPY; PIGMENT DISORDER; PIGMENTATION; PITYRIASIS; PRURITUS; PSORIASIS; REVIEW; SIDE EFFECT; SKIN PAIN; SKIN REDNESS; SKIN SENSITIVITY; SKIN TRANSPLANTATION; TINEA VERSICOLOR; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; UNSPECIFIED SIDE EFFECT; VITILIGO; XEROSIS; ARTICLE; INFLAMMATION;

CAFE-AU-LAIT SPOTS; HUMANS; INFLAMMATION; MELANOSIS; PIGMENTATION DISORDERS; VITILIGO;

EID: 60249083498     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Stulberg DL, Clark N, Tovey D. Common hyperpigmentation disorders in adults: Part I. Diagnostic approach, café-au-lait macules, diffuse hyperpigmentation, sun exposure, and phototoxic reactions. Am Fam Physician. 2003;68(10):1955-1960. (Pubitemid 37464326)
2. Fitzpatrick TB. Fitzpatrick's Dermatology in General Medicine. 4th ed. New York, NY: McGraw-Hill; 1993:966-968,1694,1984.
3. World Health Organization. Skin cancers. http://www.who.int/uv/faq/ skincancer/en/print.html. Accessed October 31, 2008.
4. Burns RL, Prevost-Blank PL, Lawry MA, Lawry TB, Faria DT, Fivenson DP. Glycolic acid peels for postinflammatory hyperpigmentation in black patients. A comparative study. Dermatol Surg. 1997;23(3):171-175. (Pubitemid 27200621)
5. Grimes P, Callender V. Tazarotene cream for postinflammatory hyperpigmentation and acne vulgaris in darker skin: a double-blind, randomized, vehicle-controlled study. Cutis. 2006;77(1):45-50. (Pubitemid 43189155)
6. West TB, Alster TS. Effect of pretreatment on the incidence of hyperpigmentation following cutaneous CO2 laser resurfacing. Dermatol Surg. 1999;25(1):15-17. (Pubitemid 29242726)
7. Erbil H, Sezer E, Tastan B, Arca E, Kurumlu Z. Efficacy and safety of serial glycolic acid peels and a topical regimen in the treatment of recalcitrant melasma. J Dermatol. 2007;34(1):25-30. (Pubitemid 46005953)
8. Fitzpatrick TB, Wolff K, Johnson RA, Suurmond D. Fitzpatrick's Color Atlas & Synopsis of Clinical Dermatology. 5th ed. New York, NY: McGraw-Hill; 2005:350-353.
9. Leenutaphong V, Nettakul A, Rattanasuwon P. Topical isotretinoin for melasma in Thai patients: a vehicle-controlled clinical trial. J Med Assoc Thai. 1999;82(9):868-875.
10. Nanda S, Grover C, Reddy BS. Efficacy of hydroquinone (2%) versus tretinoin (0.025%) as adjunct topical agents for chemical peeling in patients of melasma. Dermatol Surg. 2004;30(3):385-389. (Pubitemid 38524157)
11. Guevara IL, Pandya AG. Safety and efficacy of 4% hydroquinone combined with 10% glycolic acid, antioxidants, and sunscreen in the treatment of melasma. Int J Dermatol. 2003;42(12):966-972. (Pubitemid 38004473)
12. Haddad AL, Matos LF, Brunstein F, Ferreira LM, Silva A, Costa D Jr. A clinical, prospective, randomized, double-blind trial comparing skin whitening complex with hydroquinone vs. placebo in the treatment of melasma. Int J Dermatol. 2003;42(2):153-156. (Pubitemid 41709845)
13. Lim JT, Tham SN. Glycolic acid peels in the treatment of melasma among Asian women. Dermatol Surg. 1997;23(3):177-179. (Pubitemid 27200622)
14. Espinal-Perez LE, Moncada B, Castanedo-Cazares JP. A double-blind randomized trial of 5% ascorbic acid vs. 4% hydroquinone in melasma. Int J Dermatol. 2004;43(8):604-607. (Pubitemid 39207001)
15. Dogra S, Kanwar AJ, Parsad D. Adapalene in the treatment of melasma: a preliminary report. J Dermatol. 2002;29(8):539-540. (Pubitemid 34988258)
16. Taylor SC, Torok H, Jones T, et al. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Cutis. 2003;72(1):67-72. (Pubitemid 37229761)
17. Torok H, Taylor S, Baumann L, et al. A large 12-month extension study of an 8-week trial to evaluate the safety and efficacy of triple combination (TC) cream in melasma patients previously treated with TC cream or one of its dyads. J Drugs Dermatol. 2005;4(5):592-597.
18. Nouri K, Bowes L, Chartier T, Romagosa R, Spencer J. Combination treatment of melasma with pulsed CO2 laser followed by Q-switched alexandrite laser: a pilot study. Dermatol Surg. 1999;25(6):494-497. (Pubitemid 29279595)
19. Wang CC, Hui CY, Sue YM, Wong WR, Hong HS. Intense pulsed light for the treatment of refractory melasma in Asian persons. Dermatol Surg. 2004;30(9):1196-1200. (Pubitemid 39312239)
20. Lugo-Janer A, Lugo-Somolinos A, Sanchez JL. Comparison of trichloroacetic acid solution and cryosurgery in the treatment of solar lentigines. Int J Dermatol. 2003;42(10):829-831. (Pubitemid 37304053)
21. Almond-Roesler B, Zouboulis CC. Successful treatment of solar lentigines by brief gentle cryosurgery using a Kryomed device. Br J Dermatol. 2000;143(1):216-218. (Pubitemid 30485288)
22. Li YT, Yang KC. Comparison of the frequency-doubled Q-switched Nd: YAG laser and 35% trichloroacetic acid for the treatment of face lentigines. Dermatol Surg. 1999;25(3):202-204. (Pubitemid 29146986)
23. Todd MM, Rallis TM, Gerwels JW, Hata TR. A comparison of 3 lasers and liquid nitrogen in the treatment of solar lentigines: a randomized, controlled, comparative trial. Arch Dermatol. 2000;136(7):841-846. (Pubitemid 30604281)
24. Wang CC, Sue YM, Yang CH, Chen CK. A comparison of Q-switched alexandrite laser and intense pulsed light for the treatment of freckles and lentigines in Asian persons: a randomized, physician-blinded, splitface comparative trial. J Am Acad Dermatol. 2006;54(5):804-810.
25. Petit L, Piérard GE. Analytic quantification of solar lentigines lightening by a 2% hydroquinone-cyclodextrin formulation. J Eur Acad Dermatol Venereol. 2003;17(5):546-549. (Pubitemid 37138893)
26. Draelos ZD. Novel approach to the treatment of hyperpigmented photodamaged skin: 4% hydroquinone/0.3% retinol versus tretinoin 0.05% emollient cream. Dermatol Surg. 2005;31(7 pt 2):799-804.
27. Fleischer AB Jr, Schwartzel EH, Colby SI, Altman DJ. The combination of 2% 4-hydroxyanisole (Mequinol) and 0.01% tretinoin is effective in improving the appearance of solar lentigines and related hyperpigmented lesions in two double-blind multicenter clinical studies. J Am Acad Dermatol. 2000;42(3):459-467. (Pubitemid 30470354)
28. Jarratt M. Mequinol 2%/tretinoin 0.01% solution: an effective and safe alternative to hydroquinone 3% in the treatment of solar lentigines. Cutis. 2004;74(5):319-322. (Pubitemid 39612341)
29. Kang S, Goldfarb MT, Weiss JS, et al. Assessment of adapalene gel for the treatment of actinic keratoses and lentingines: a randomized trial. J Am Acad Dermatol. 2003;49(1):83-90. (Pubitemid 36801637)
30. Kang S, Kreuger GG, Tanghetti EA, et al., for the Tazarotene Cream in Photodamage Study Group. A multicenter, randomized, double-blind trial of tazarotene 0.1% cream in the treatment of photodamage. J Am Acad Dermatol. 2005;52(2):268-274.
31. Fathman EM, Habif TP. Skin Disease: Diagnosis and Treatment. 1st ed. St. Louis, Mo.: Mosby; 2001:58,184-186,308-311,469.
32. Kawalek AZ, Spencer JM, Phelps RG. Combined excimer laser and topical tacrolimus for the treatment of vitiligo: a pilot study. Dermatol Surg. 2004;30(2 pt 1):130-135. (Pubitemid 38313998)
33. Stulberg DL, Clark N, Tovey D. Common hyperpigmentation disorders in adults: Part II: Melanoma, seborrheic keratoses, acanthosis nigricans, melasma, diabetic dermopathy, tinea vessicolor, and postinflammatory hyperpigmentation. Am Fam Physician. 2003;68(10):1963-1968. (Pubitemid 37464327)
34. Kumaran MS, Kaur I, Kumar B. Effect of topical calcipotriol, betamethasone dipropionate and their combination in the treatment of localized vitiligo. J Eur Acad Dermatol Venereol. 2006;20(3):269-273.
35. Lepe V, Moncada B, Castanedo-Cazares JP, Torres-Alvarez MB, Ortiz CA, Torres-Rubalcava AB. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol. 2003;139(5):581-585. (Pubitemid 36576373)
36. Passeron T, Ostovari N, Zakaria W, et al. Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo. Arch Dermatol. 2004;140(9):1065-1069. (Pubitemid 39223113)
37. Mehrabi D, Pandya AG. A randomized, placebo-controlled, double-blind trial comparing narrowband UV-B plus 0.1% tacrolimus ointment with narrowband UV-B plus placebo in the treatment of generalized vitiligo. Arch Dermatol. 2006;142(7):927-929. (Pubitemid 44079798)
38. Leone G, Pacifico A, Iacovelli P, Paro Vidolin A, Picardo M. Tacalcitol and narrow-band phototherapy in patients with vitiligo. Clin Exp Dermatol. 2006;31(2):200-205.
39. Valkova S, Trashlieva M, Christova P. Treatment of vitiligo with local khellin and UVA: comparison with systemic PUVA. Clin Exp Dermatol. 2004;29(2):180-184. (Pubitemid 38367205)
40. Arca E, Tastan HB, Erbil AH, Sezer E, Koc E, Kurumlu Z. Narrow-band ultraviolet B as monotherapy and in combination with topical calcipotriol in the treatment of vitiligo. J Dermatol. 2006;33(5):338-343. (Pubitemid 43943367)
41. Tjioe M, Gerritsen MJ, Juhlin L, van de Kerkhof PC. Treatment of vitiligo vulgaris with narrow band UVB (311 nm) for one year and the effect of addition of folic acid and vitamin B12 [published correction appears in Acta Derm Vernereol. 2002;82(6):485]. Acta Derm Vernereol. 2002;82(5):369-372.
42. Hamzavi I, Jain H, McLean D, Shapiro J, Zeng H, Lui H. Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index. Arch Dermatol. 2004;140(6):677-683. (Pubitemid 38747282)
43. Njoo MD, Westerhof W, Bos JD, Bossuyt PM. The development of guidelines for the treatment of vitiligo. Clinical Epidemiology Unit of the Istituto Dermopatico dell'Immacolata-Istituto di Recovero e Cura a Carattere Scientifico (IDI-IRCCS) and the Archives of Dermatology. Arch Dermatol. 1999;135(12):1514- 1521.
44. Whitton ME, Ashcroft DM, Barrett CW, Gonzalez U. Interventions for vitiligo. Cochrane Database Syst Rev. 2006;(1):CD003263.
45. Barman KD, Khaitan BK, Verma KK. A comparative study of punch grafting followed by topical corticosteroid versus punch grafting followed by PUVA therapy in stable vitiligo. Dermatol Surg. 2004;30(1):49-53. (Pubitemid 38174029)